AxoGen Azione

AxoGen Debiti verso fornitori

Il Debiti Commerciali di AxoGen (AXGN) al 14 ago 2026 è 2,89 Mio. USD. L'anno precedente, Debiti Commerciali era 8,01 Mio. USD — una variazione del -63,94% (inferiore).

Debiti verso fornitori

2,89 Mio.USD

YoY

-63,94%

Ultimo aggiornamento:

Debiti Commerciali di AxoGen ammonta a 2026 2,89 Mio. USD. Debiti Commerciali di AxoGen ammontava a 2025 8,01 Mio. USD. Diminuisce del -63,94% inferiore rispetto all'anno precedente.
Access this data via the Eulerpool API

AxoGen Analisi delle Azioni

Cosa fa AxoGen? AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su AxoGen azioni

Debiti Commerciali di AxoGen è 2,89 Mio. USD nel 2026.

Il Debiti Commerciali di AxoGen è passato da 8,01 Mio. USD a 2,89 Mio. USD, con una variazione del -63,94 %. Il valore è inferiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del AxoGen di Debiti Commerciali dal 2006, con valori annuali, grafici e analisi dettagliate.

I debiti commerciali rappresentano il denaro dovuto ai fornitori per beni e servizi ricevuti. È un componente fondamentale della gestione del capitale di esercizio.

Il USD di Debiti Commerciali è un fattore chiave per gli investitori. I cambiamenti in questa metrica possono segnalare il miglioramento o il deterioramento dei fondamentali, impattando direttamente il prezzo delle azioni. Su Eulerpool puoi tracciare il AxoGen di Debiti Commerciali storicamente e in tempo reale.

Access this data via the Eulerpool API

Bilancio — AxoGen

Tutte le Metriche Finanziarie — AxoGen